Recombinant Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR12733] to LOXL2 - C-terminal
- Suitable for: WB
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-LOXL2 antibody [EPR12733] - C-terminal
See all LOXL2 primary antibodies -
Description
Rabbit monoclonal [EPR12733] to LOXL2 - C-terminal -
Host species
Rabbit -
Specificity
Our lab has been unable to use this product successfully in IHC-P and so we cannot guarantee that it will work in this application. However, some customers have been successful with this antibody in IHC-P. -
Tested applications
Suitable for: WBmore details
Unsuitable for: IP -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide within Human LOXL2 aa 750 to the C-terminus (C terminal) (Cysteine residue). The exact sequence is proprietary.
Database link: Q9Y4K0 -
Positive control
- WB: MDA-MB-435, A431, U87-MG, and HeLa cell lysates.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR12733 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab179810 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (2) |
1/200 - 1/1000. Predicted molecular weight: 87 kDa.
|
Notes |
---|
WB
1/200 - 1/1000. Predicted molecular weight: 87 kDa. |
Target
-
Tissue specificity
Expressed in many tissues. Highest expression in reproductive tissues, placenta, uterus and prostate. -
Sequence similarities
Belongs to the lysyl oxidase family.
Contains 4 SRCR domains. -
Post-translational
modificationsThe lysine tyrosylquinone cross-link (LTQ) is generated by condensation of the epsilon-amino group of a lysine with a topaquinone produced by oxidation of tyrosine. -
Cellular localization
Secreted > extracellular space. - Information by UniProt
-
Database links
- Entrez Gene: 4017 Human
- Entrez Gene: 94352 Mouse
- Entrez Gene: 290350 Rat
- Omim: 606663 Human
- SwissProt: Q9Y4K0 Human
- SwissProt: P58022 Mouse
- SwissProt: B5DF27 Rat
- Unigene: 626637 Human
see all -
Alternative names
- LOR 2 antibody
- LOR2 antibody
- LOX L2 antibody
see all
Images
-
All lanes : Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/500 dilution
Lane 1 : Wild-type HeLa cell lysate
Lane 2 : LOXL2 knockout HeLa cell lysate
Lane 3 : HeLa treated with 0.5nM CoCl2 for 6 hours whole cell lysate
Lane 4 : Untreated HeLa cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 87 kDa
Observed band size: 105 kDa why is the actual band size different from the predicted?Lanes 1-4: Merged signal (red and green). Green - ab179810 observed at 105 kDa. Red - loading control, ab8245 observed at 37 kDa.
ab179810 Anti-LOXL2 antibody [EPR12733] - C-terminal was shown to specifically react with LOXL2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab264807 (knockout cell lysate ab257166) was used. Wild-type and LOXL2 knockout samples were subjected to SDS-PAGE. ab179810 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
-
All lanes : Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/500 dilution
Lane 1 : Wild-type HeLa cell lysate
Lane 2 : LOXL2 knockout HeLa cell lysate
Lane 3 : HeLa treated with 0.5nM CoCl2 for 6 hours whole cell lysate
Lane 4 : Untreated HeLa cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 87 kDa
Observed band size: 105 kDa why is the actual band size different from the predicted?Lanes 1-4: Merged signal (red and green). Green - ab179810 observed at 105 kDa. Red - loading control, ab8245 observed at 37 kDa.
ab179810 Anti-LOXL2 antibody [EPR12733] - C-terminal was shown to specifically react with LOXL2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab261804 (knockout cell lysate ab257168) was used. Wild-type and LOXL2 knockout samples were subjected to SDS-PAGE. ab179810 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
-
Lanes 1-2 & 4 : Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/1000 dilution
Lane 3 : Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/200 dilution
Lane 1 : MCF-7 (Human breast carcinoma) whole cell lysate
Lane 2 : MDA-MB-435 (Human ductal carcinoma) whole cell lysate
Lane 3 : A431 (Human epidermoid carcinoma) whole cell lysate
Lane 4 : U87-MG (Human glioblastoma) whole cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 87 kDa
Observed band size: 105 kDa why is the actual band size different from the predicted?Exposure time:
Lane 1-3: 3min
Lane 4: 1minBlocking/Diluting buffer and concentration 5% NFDM /TBST
MCF-7 lack LOXL2 expression (PMID: 19330836, PMID:12154058 and PMID: 27655685)
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (14)
ab179810 has been referenced in 14 publications.
- Li N et al. Inhibitory effects of LOXL2 knockdown on cellular functions of liver cancer stem cells. Transl Cancer Res 11:2013-2025 (2022). PubMed: 35966289
- Cui Y et al. A novel epithelial-mesenchymal transition (EMT)-related gene signature of predictive value for the survival outcomes in lung adenocarcinoma. Front Oncol 12:974614 (2022). PubMed: 36185284
- Wen L et al. Phenylethanol glycosides from Herba Cistanche improve the hypoxic tumor microenvironment and enhance the effects of oxaliplatin via the HIF-1a signaling pathway. Mol Med Rep 24:N/A (2021). PubMed: 34013363
- Wang H et al. An in situ activity assay for lysyl oxidases. Commun Biol 4:840 (2021). PubMed: 34226627
- Klepfish M et al. LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis. Front Immunol 11:480 (2020). PubMed: 32296422